Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the change from baseline in hemoglobin A1C
achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin
XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral
administration of double-blind treatment. The safety of treatment with dapagliflozin will
also be assessed in this study